EMEA-002270-PIP04-20

Table of contents

Key facts

Active substance
Marzeptacog alfa (activated)
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0482/2021
PIP number
EMEA-002270-PIP04-20
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Treatment of Haemophilia B
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Catalyst Biosciences, Inc.

Email: cdemocko@catbio.com    
Tel. +1 4153054942

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating